- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06175234
Feasibility Study on the FARAVIEW Technology (NAVIGATE PF)
A Study Evaluating the User Experience With the FARAVIEW™ Technology of the RHYTHMIA HDx™ Mapping System When Used With the FARAWAVE NAV™ Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
Study Overview
Status
Intervention / Treatment
Detailed Description
The objective of this study is to obtain First-in-Human (FIH) experience with the FARAVIEW™ technology of the RHYTHMIA HDx™ Mapping System when it is used to visualize and track the FARAWAVE NAV™ Pulsed Field Ablation (PFA) catheter in the treatment of Atrial Fibrillation (AF). The study will collect FIH data on user experience and workflow using the FARAVIEW technology to visualize and track the FARAWAVE NAV PFA catheter (part of the FARAPULSE™ Pulsed Field Ablation System).
Subjects with Paroxysmal and Persistent Atrial Fibrillation will be included in this study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sharda Mehta
- Phone Number: +16785967330
- Email: sharda.mehta@bsci.com
Study Locations
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra
-
Contact:
- José Ignacio García Bolao, MD
- Email: igarciab@unav.es
-
Principal Investigator:
- José Ignacio Garcia Bolao, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: ≥ 18 years of age, or older if required by local law
Symptomatic, documented, drug-resistant, Atrial Fibrillation
- Documented: at a minimum a physician's note confirming the arrhythmia symptoms and durations AND within 180 days of the Enrollment Date one (1) ECG from any regulatory cleared rhythm monitoring device showing AF
- Drug-resistant: effectiveness failure of, intolerance to, or specific contraindication to at least one (1) AAD (Class I, II, III or IV) 1
- Informed consent: willing and capable of providing informed consent
- Full participation: willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center
Exclusion Criteria:
Atrial exclusions - Any of the following atrial conditions:
- Prior atrial ablation: any prior atrial endocardial, epicardial or surgical ablation procedure for arrhythmia other than ablation for right sided SVT or cavotricuspid isthmus ablation
- Atrial myxoma: current atrial myxoma
- Pulmonary veins: any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
- Atrial thrombus: current left atrial thrombus
- Long standing persistent AF: continuous AF lasting longer than 12 months
Cardiovascular exclusions - Any of the following CV conditions:
- Ventricular arrhythmia: history of sustained ventricular tachycardia or any ventricular fibrillation
- Secondary AF: AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes
- Cardiac devices and implants: current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices, interatrial baffle, closure device, patch, or patent foramen ovale or ASD occluder, LA appendage closure, device or occlusion.
- Clinically significant valvular disease: valvular disease that is any of the following:
i. Symptomatic ii. Causing or exacerbating congestive heart failure iii. Associated with abnormal LV function or hemodynamic measurements e. Cardiomyopathy i. Hypertrophic cardiomyopathy ii. Cardiac amyloidosis f. Valve prostheses: any prosthetic heart valve, ring or repair including balloon aortic valvuloplasty g. Access issues: any IVC filter, known inability to obtain vascular access or other contraindication to femoral access h. Rheumatic disease: rheumatic heart disease i. Anticipated cardiac surgery: awaiting cardiac transplantation or other cardiac surgery within the next 12 months
Any of the following conditions at baseline (Section 10.4):
- Heart failure NYHA Heart failure associated with NYHA IV
- Ejection fraction: LVEF < 40%
Any of the following events within 90 Days of the Consent Date:
- Coronary disease: myocardial infarction (MI), unstable or coronary intervention
- Cardiac surgery: any cardiac surgery
- Heart failure hospitalization: heart failure hospitalization
- Pericardium: pericarditis or symptomatic pericardial effusion
- GI bleeding: gastrointestinal bleeding
- Neurovascular event: stroke, TIA, or intracranial bleeding
- Thromboembolism: any non-neurologic thromboembolic event
- Carotid intervention: carotid stenting or endarterectomy
- Bleeding diathesis: thrombocytosis, thrombocytopenia, disorder of blood clotting or bleeding diathesis
- Contraindication to anticoagulation: contraindication to, or unwillingness to use, systemic anticoagulation
- Pregnancy: women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period
Health conditions that in the investigator's medical opinion would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation, including but not limited to:
- Obesity: Body Mass Index (BMI) > 45.0
- Transplantation: solid organ or hematologic transplant, or currently being evaluated for a transplant
- Diaphragmatic abnormality: any prior history or current evidence of hemi-diaphragmatic paralysis or paresis
- Pulmonary: severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
- Renal: renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL / min / 1.73 m2, or with any history of renal dialysis or renal transplant
- Malignancy: active malignancy (other than cutaneous basal cell or squamous cell carcinoma)
- Gastrointestinal: clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration
- Infections: active systemic infection
- COVID-19 disease: known positive test for COVID-19 and disease not clinically resolved
- Life expectancy: predicted life expectancy less than one (1) year
- Participation in another trial: subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility
- Congenital heart disease: congenital heart disease with any clinically significant residual anatomic or conduction abnormality
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Catheter ablation for Paroxysmal or Persistent Atrial Fibrillation
Subjects scheduled to undergo endocardial mapping and Pulmonary Vein Isolation (PVI) in the treatment of atrial fibrillation.
For patients with persistent AF, left atrial posterior wall isolation (PWI) may also be performed in addition to PVI at the discretion of the investigator
|
For subjects with paroxysmal AF, Pulmonary Vein Isolation will be performed with the FARAWAVE NAV catheter.
For subjects with persistent AF, left atrial posterior wall isolation (PWI) may also be performed at the discretion of the investigator, with the FARAWAVE NAV PFA catheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with PVI success
Time Frame: At the end of the ablation procedure
|
PVI success is defined as the proportion of veins isolated vs reconnected at the end of the procedure as assessed by a site's standard of care method for testing vein isolation
|
At the end of the ablation procedure
|
Number of subjects with PWI success
Time Frame: At the end of the ablation procedure
|
PWI success is defined as the isolation of the left atrial PW at the end of the procedure as assessed by a site's standard of care method for testing
|
At the end of the ablation procedure
|
Physician feedback on FARAVIEW technology of the RHYTHMIA mapping system by means of a questionnaire
Time Frame: At the end of the ablation procedure
|
Physician feedback on the FARAVIEW technology of the RHYTHMIA mapping system will be collected by means of a questionnaire.
|
At the end of the ablation procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PF305
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Ablation Treatment
-
Fatih Sultan Mehmet Training and Research HospitalCompleted
-
Jonsson Comprehensive Cancer CenterMedtronic; Jean Perkins FoundationCompleted
-
CathVision ApSAKRN ConsultingRecruitingAtrial FibrillationBelgium
-
Henry Ford Health SystemTerminatedChronic Knee PainUnited States
-
International Agency for Research on CancerReferral Centre of Reproductive Health, Fez, Morocco; Referral Centre of Reproductive...CompletedCervical NeoplasmMorocco
-
Neurotronic, Inc.Libra MedicalRecruitingAblation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR IV)Hypertension | Diabetes Mellitus, Type 2Georgia
-
Sacramento EP ResearchPadraig Gearoid O'Neill, MD; Mark R. Bowers, MS, MD; Anna M. Thiemann, BA; Shelley... and other collaboratorsCompletedParoxysmal Atrial FibrillationUnited States
-
Beijing Tsinghua Chang Gung HospitalActive, not recruiting
-
Scientific Institute San RaffaeleRecruitingArrhythmia | Myocarditis | Cardiomyopathies | Ventricular Arrythmia | Immunosuppression | Genetic Predisposition | Inflammatory Cardiomyopathy | Catheter Ablation | AutoimmunityItaly
-
InSightecUnknown